Taking your genes in hand
By The Economist,
The Economist
| 12. 06. 2007
Personal genetic testing is advancing rapidly. But beware of overselling
GENETIC testing promises a lot. In particular, it promises to tell people things ranging from their risks of developing ailments as diverse as heart disease, cancer and autism to how much coffee they can safely drink. It also promises a lucrative market for those doing the testing. Single-gene tests, such as those for particular forms of genes that predispose people to breast cancer, have been available for a while. This year, however, has seen the arrival of commercial versions of techniques that can sample a person's entire genetic make-up, and do so in a way that will enable him to benefit from future discoveries as well as existing knowledge.
In many cases, knowing the risk will also allow (and might, indeed, encourage) someone to modify his behaviour to avoid a disease he is at risk of—or, failing that, to mitigate its consequences. Nevertheless, concerns are being raised about the accuracy of some tests now on the market, and also their usefulness when the results are supplied direct to consumers, rather...
Related Articles
By Alex Aylward, Daniel J. Fairbanks, Maria Kiladi, and Gregory Radick , Heredity | 04.20.2026
Genetics and eugenics co-evolved at the beginning of the twentieth century and remained associated through the 1940s and beyond. Early geneticists were far from unanimous in their views on eugenics; some avidly supported the movement, whereas others openly opposed it...
By Staff, GMWatch | 03.28.2026
Following a recent podcast interview we were asked whether there is any solid scientific research looking at how gene expression or molecular composition in genetically modified (GM) plants differs from conventionally bred plants. As this is an interesting and important...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...